Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


siRNA Opening Up CNS Device Opportunities

This article was originally published in Start Up

Executive Summary

The neurodegenerative disease R&D collaboration between RNA interference specialist Alnylam and device maker Medtronic--the first siRNA-oriented convergence opportunity--appears to be inching closer to the clinic. Key to the program's success to date are refinements in the Medtronic catheter and infusion -pump system used to deliver the Alnylam compund, in keeping with Medtronic's strategic goal of better understanding the mechanics of delivering chronic drugs into the brain.

Related Content

Building Medtronic Neuro by Trial: An Interview with Richard Kuntz, MD
Neurostimulation Market Expanding
Medtronic: Making Convergence Pay


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts